Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
Diagnostic methods for assessing risk of or presence of inflammatory bowel disease in a patient based on glycosyltransferase or histo-blood group antigen signatures or a combination thereof. Also disclosed herein are prognostic methods for monitoring inflammatory bowel disease progression in a patient.
1. A method for diagnosing and treating inflammatory bowel disease, the method comprising:
measuring a level of one or more human blood group antigens in a tissue sample of a human subject suspected of having an inflammatory bowel disease (IBD), wherein the IBD is Intestinal Colitis, Ulcerative Colitis, or Crohn's disease,
determining a profile of the one or more human blood group antigens in the tissue sample,
identifying the human subject as having or at risk for IBD based on the profile of the one or more human blood group antigens, and
treating the human subject with an anti-inflammatory agent, an immune suppressant agent, an antibiotic agent, or a combination thereof;
wherein the one or more human blood group antigens comprise one or more of sialyl Lewis x (sLe x ), Lewis x (Le x ), and Lewis b (Le b ).
2. The method of claim 1 , wherein the one or more human blood group antigens comprise sLe x , and wherein the expression profile representing an elevated level of the one or more human group blood group antigens indicates that the human subject has or is at risk for the IBD.
3. The method of claim 2 , wherein the one or more human blood group antigens further comprise Le b .
4. The method of claim 1 , wherein the at least one or more human blood group antigens further comprise an H antigen, and wherein the expression profile representing a reduced level of the H antigen indicates that the human subject has or is at risk for IBD.
5. The method of claim 1 , wherein the tissue sample is an intestinal sample, a colon biopsy sample, a biofluid sample, a saliva sample, or a stool sample.
6. The method of claim 1 , wherein the level of the one or more human blood antigens is measured by an immune assay, agglutination inhibition assay, or flow cytometry.
7. The method of claim 1 , wherein the one or more human blood group antigens comprises sLe x and Le x .
8. The method of claim 1 , wherein the one or more human blood group antigens further comprise sialyl Lewis a (sLe a ).